Result Serum: The result is reported as negative, borderline or positive with a value (blot intensity).
CSF: The result is reported as negative, borderline or positive
Interpretation Antibodies against Tr (Trotter antigen, DNER) can be seen in breast or ovarian cancer, small cell lung cancer, thymoma, Hodgkins lymphoma and are associated to paraneoplastic encephalomyelit or cerebellar degeneration.
Antibodies against Tr are graded as Higher-risk antibodies with a frequency of 90% of underlying cancer and a positive result yield 3 points PNS score, according to Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
References
Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011 Jul 12;77(2):179-89. PMID: 21747075
Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4):e1014. PMID: 34006622
Can't find what you're looking for? We are here to help
ENSKILD ANALYS 760
Tr (Purkinjecell)-antikroppar (IgG)
Indikation Misstanke om paraneoplastiskt syndrom.
Metod Immunoblot.
Svar Serum: Resultatet anges som negativt, gränsvärde eller positivt med värde (blot intensitet).
Likvor: Resultatet anges som negativt, gränsvärde eller positivt.
Tolkning Antikroppar mot Tr (Trotter antigen, DNER) kan ses vid bröst- eller ovariecancer, småcellig lungcancer, thymom samt vid Hodgkins lymfom och är associerade med paraneoplastisk encephalomyelit eller cerebellär degeneration.
Antikropparna riktade mot Tr bedöms vara Higher-risk antibodies med en förkomst på 90 % för en underliggande cancer och positivitet ger 3 poäng i PNS score enligt Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes.
Referenser
Lancaster E, Martinez-Hernandez E, Dalmau J. Encephalitis and antibodies to synaptic and neuronal cell surface proteins. Neurology. 2011 Jul 12;77(2):179-89. PMID: 21747075
Graus F, et al. Updated Diagnostic Criteria for Paraneoplastic Neurologic Syndromes. Neurol Neuroimmunol Neuroinflamm. 2021 May 18;8(4):e1014. PMID: 34006622